Nagl, Laurenz
Pall, Georg
Wolf, Dominik
Pircher, Andreas
Horvath, Lena http://orcid.org/0000-0002-1509-4324
Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Received: 20 May 2022
Accepted: 24 June 2022
First Online: 19 July 2022
Conflict of interest
: G. Pall has received speaker fees and is an advisory board member of Astra Zeneca, Roche, Böhringer Ingelheim, Pfizer, Takeda, Lilly, Janssen, Novartis, Merck, Amgen, Daichii-Sankyo. D. Wolf has received speaker fees from MSD, Pfizer, Roche, Novartis, BMS/Celgene and Astra Zeneca. A. Pircher has received speaker fees and honoraria for advisory boards from Astra Zeneca, BMS, Roche, Pfizer, Takeda and MSD. L. Nagl and L. Horvath have received travel fees from MSD.